OssDsign's third-quarter net sales fall 5.4%, in line with company expectations
Swedish orthobiologics developer OssDsign reported a 5.4% year-on-year drop in Q3 net sales, while its adjusted EBIT loss widened. Reported by Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Reuters, citing LSEG and company data, net sales at Swedish orthobiologics developer OssDsign fell 5.4% year on year in the third quarter. The company said the decline was in line with its own expectations. Gross margin improved from the previous quarter thanks to a better product and customer mix, and lower operating expenses offset most of the shortfall in gross profit.
Sales came in at SEK 35.73 million, below the SEK 36.50 million estimate from two analysts. The net loss was SEK 5.78 million, and adjusted free cash flow was negative at SEK 5.26 million. The company also said that more than 400 patients had been entered in the PROPEL spine registry for its OssDsign Catalyst product. It did not give specific guidance for the current quarter or the full year.
why it matters
For the broader market this is a minor story: OssDsign is a small medtech company, and its results rarely move indexes or commodity markets. The report may interest investors following Swedish medical technology stocks.
tags
instruments
sources
- Sweden's OssDsign Q3 net sales fall 5.4%, as expected — Reuters, 3 November 2026 at 06:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗